Type C Thymoma

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Type C Thymoma

MalaCards integrated aliases for Type C Thymoma:

Name: Type C Thymoma 12 15
Thymoma, Type C 12 74


External Ids:

Disease Ontology 12 DOID:4554
NCIt 51 C7569
UMLS 74 C1322286

Summaries for Type C Thymoma

MalaCards based summary : Type C Thymoma, also known as thymoma, type c, is related to thymic carcinoma and thymus cancer. An important gene associated with Type C Thymoma is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways is Neurotrophic factor-mediated Trk receptor signaling. The drugs Fentanyl and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include thyroid, thymus and pituitary, and related phenotype is nervous system.

Related Diseases for Type C Thymoma

Graphical network of the top 20 diseases related to Type C Thymoma:

Diseases related to Type C Thymoma

Symptoms & Phenotypes for Type C Thymoma

MGI Mouse Phenotypes related to Type C Thymoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.02 CD5 NTF4 NTRK3 SST SSTR2

Drugs & Therapeutics for Type C Thymoma

Drugs for Type C Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
4 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
5 Liver Extracts Phase 3,Phase 1
6 Cola Phase 3,Phase 1,Not Applicable
7 Narcotics Phase 3
8 Adjuvants, Anesthesia Phase 3
9 Analgesics Phase 3,Phase 1
10 Anesthetics, Intravenous Phase 3
11 Anesthetics, General Phase 3
12 Anesthetics Phase 3
13 Analgesics, Opioid Phase 3
14 Central Nervous System Depressants Phase 3,Not Applicable
15 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
16 Etoposide phosphate Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
leucovorin Approved Phase 2 58-05-9 143 6006
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
Bevacizumab Approved, Investigational Phase 2 216974-75-3
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
Busulfan Approved, Investigational Phase 2 55-98-1 2478
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
Melphalan Approved Phase 2 148-82-3 460612 4053
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
Rabeprazole Approved, Investigational Phase 1, Phase 2 117976-89-3 5029
Nedaplatin Approved, Investigational Phase 2 95734-82-0
nivolumab Approved Phase 2,Phase 1 946414-94-4
Ramucirumab Approved, Investigational Phase 2 947687-13-0
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
Coal tar Approved Phase 1, Phase 2 8007-45-2
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2,Phase 2 60-18-4 6057
49 Amrubicin Investigational Phase 2 110267-81-7
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
3 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
4 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
5 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
6 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
7 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
8 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2 cisplatin and etoposide
9 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
10 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
11 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
12 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
13 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
14 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
15 Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors Completed NCT01283945 Phase 1, Phase 2 Lucitanib
16 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
17 Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
18 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Recruiting NCT03134118 Phase 2 Nivolumab
19 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
20 Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Recruiting NCT03921671 Phase 2
21 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
22 Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Recruiting NCT03463460 Phase 2 Sunitinib Malate
23 Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Recruiting NCT03466827 Phase 2 Selinexor
24 Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
25 Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
26 A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting NCT01325441 Phase 1, Phase 2 BBI608;Paclitaxel
27 Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Recruiting NCT03193437 Phase 2 Open Label Selinexor
28 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2 Everolimus
29 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
30 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
31 Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors Active, not recruiting NCT02636556 Phase 2
32 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
33 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Active, not recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
34 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Terminated NCT01011439 Phase 2 Milciclib Maleate
35 Paclitaxel and Cisplatin for Thymic Neoplasm Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
36 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2 saracatinib
37 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide
38 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
39 Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Completed NCT00314873 Phase 1 Gleevec (imatinib)
40 Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Completed NCT01143545 Phase 1 Celecoxib;cyclophosphamide
41 Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Completed NCT00921739 Phase 1
42 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
43 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03295227 Phase 1 Pembrolizumab
44 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
45 SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access Unknown status NCT02214134
46 Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer Unknown status NCT00372840 Not Applicable
47 Biology of Thymic Tumors Completed NCT00965627
48 Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment Completed NCT03078699 Not Applicable
49 Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Completed NCT02062632 Not Applicable Doxepin Hydrochloride
50 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572

Search NIH Clinical Center for Type C Thymoma

Genetic Tests for Type C Thymoma

Anatomical Context for Type C Thymoma

MalaCards organs/tissues related to Type C Thymoma:

Thyroid, Thymus, Pituitary, Testes

Publications for Type C Thymoma

Articles related to Type C Thymoma:

# Title Authors Year
Advanced pediatric inoperable thymus carcinoma (type C thymoma): case report on a novel therapeutic approach. ( 17984697 )

Variations for Type C Thymoma

Expression for Type C Thymoma

Search GEO for disease gene expression data for Type C Thymoma.

Pathways for Type C Thymoma

Pathways related to Type C Thymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
10.41 NTF4 NTRK3

GO Terms for Type C Thymoma

Biological processes related to Type C Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.16 NTF4 NTRK3
2 negative regulation of cell death GO:0060548 8.96 NTF4 NTRK3
3 mechanoreceptor differentiation GO:0042490 8.62 NTF4 NTRK3

Sources for Type C Thymoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
33 HPO
34 ICD10
35 ICD10 via Orphanet
39 LifeMap
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
56 Novoseek
59 OMIM via Orphanet
63 PubMed
71 SNOMED-CT via Orphanet
73 Tocris
75 UMLS via Orphanet
Loading form....